Flurbiprofen to Prevent Intraoperative Miosis During Cataract IOL Surgery

Sawang Ponglertnapakorn M.D.,
Prut Hanutsaha M.D.,
Skowrat Kunavisarut M.D.,
Tiam Lawtiantong M.D.,
Department of Ophthalmology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

ABSTRACT During October 1989 to April 1990, seventy one patients were enrolled in a randomized, double blind controlled trial to study the efficacy of flurbiprofen in preventing intraoperative miosis during cataract IOL surgery.

The patients were divided into 4 groups, 3 patients received 1 % tropicamide alone, 23 patients received 1% tropicamide and 10% phenylephrine, 7 patients received 1% tropicamide and 0.03% flurbiprofen, and 38 patients received 1% tropicamide and 10% phenylephrine and 0.03% flurbiprofen.

The mean changes of the pupillary diameter after conjunctival incision and after IOL insertion in each group were 0.26, 1.30, 0.58 and 0.72 mm respectively. The mean decrease of pupillary diameter in flurbiprofen treated group (group 4) was lesser than that of the non flurbiprofen treated group (group 2) with statistically significant (p=0.002). There was no difference in the effect of flurbiprofen in diabetic and non-diabetic patients. Therefore, we concluded that flurbiprofen have clinical role in preventing miosis during cataract IOL surgery in diabetic and non diabetic patients.